Eton Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Eton Pharmaceuticals, Inc. (ETON) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $16.96 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $16.01, a 20.83% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $13.25, a 199.77% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.42, a 27.38% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.47.
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $13.12, a 171.64% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $4.83, a 37.61% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.51.
- Eton Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $4.26.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.96 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $16.01 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $13.12 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $13.12 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $13.37 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $13.25 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $4.83 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $4.41 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $4.41 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $4.42 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $3.51 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $3.49 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.47 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $3.47 10-Q · filed 2023-05-11 | |||
| 2019-03-31 | $7.33 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $4.26 10-K · filed 2019-03-25 | |||
| 2018-09-30 | $3.00 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |